Benzinga

Benzinga

Benzinga

martes, septiembre 01

Kymera Therapeutics Inc

KYMRNASDAQ
Trade with Public
Trade with Public
$118.81
0.660.56%
al cierre: Aug 31, 5:00 PM EST
$118.81
N/A
After hour: 4:04 PM EST
Panorámica generalNoticiasPrevisión de beneficiosEventosPrecios objetivoFinanzasSentimientoPropiedadCompararOpcionesInforme de acciones

Kymera Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Kymera Therapeutics (KYMR).

Price Target Range — 12 Quarters

Analyst Consensus — 23 Analysts

20Buy
3Hold
Consensus RatingBuy# Analysts23Avg. Consensus PT$110Upside to Avg. PT-7.6%

Rating Trend — Last 9 Months

Recent Analyst Actions

View all ratings →
DateFirmAnalystActionRating ChangePrice Target
Aug 31, 2026GuggenheimBrad CaninoPT RaiseBuy$135→$170
Aug 27, 2026Wells FargoDerek ArchilaPT RaiseOverweight$116→$151
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Guggenheim Maintains Buy on Kymera Therapeutics, Raises Price Target to $170

Guggenheim analyst Brad Canino maintains Kymera Therapeutics (NASDAQ:KYMR) with a Buy and raises the price target from $135 to $170.
Benzinga Newsdesk

PRO
Wells Fargo Maintains Overweight on Kymera Therapeutics, Raises Price Target to $151

Wells Fargo analyst Derek Archila maintains Kymera Therapeutics (NASDAQ:KYMR) with a Overweight and raises the price target from $116 to $151.
Benzinga Newsdesk

PRO
Barclays Maintains Overweight on Kymera Therapeutics, Raises Price Target to $139

Barclays analyst Eliana Merle maintains Kymera Therapeutics (NASDAQ:KYMR) with a Overweight and raises the price target from $133 to $139.
Benzinga Newsdesk

This SK Hynix Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Thursday

Top Wall Street analysts changed their outlook on various stocks. Check out the analyst ratings page for upgrades, downgrades, and initiations.
Avi Kapoor

PRO
Deutsche Bank Initiates Coverage On Kymera Therapeutics with Hold Rating, Announces Price Target of $120

Deutsche Bank analyst David Hoang initiates coverage on Kymera Therapeutics (NASDAQ:KYMR) with a Hold rating and announces Price Target of $120.
Benzinga Newsdesk

PRO
Guggenheim Maintains Buy on Kymera Therapeutics, Raises Price Target to $135

Guggenheim analyst Brad Canino maintains Kymera Therapeutics (NASDAQ:KYMR) with a Buy and raises the price target from $125 to $135.
Benzinga Newsdesk

Datos y APIs: APIs de Benzinga · API de noticias de acciones · API de calificaciones de analistas · API de logotipos de empresas

Datos de mercado proporcionados por APIs de Benzinga

Benzinga

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

© 2026 Benzinga | All Rights Reserved